Evidence map›Paper›PMID 41773746›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

AML-Targeted Metal-Polyphenol Nanoplatform Induces Ferroptosis-ICD Cascade for Antitumor Immunity Boosting.

Shangqin Yang, Jingxuan Wang, Kerong Tu, Xiaobing Huang, Liangliang Lv, Mingjie Peng, Qiqi Xu, Hongmei Liu, Qiang Sun, Lulu Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shangqin YangDepartment of Hematology, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Jingxuan WangDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Kerong TuDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xiaobing HuangDepartment of Hematology, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Liangliang LvSchool of Pharmacy, Southwest Medical University, Luzhou, China.
Mingjie PengCollege of Pharmacy, Chengdu University, Chengdu, China.
Qiqi XuDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Hongmei LiuDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Qiang SunDepartment of Hematology, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Lulu CaiDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0002-5678-1112

Funding

Chengdu Science and Technology Project 2024-YF05-01487-SNChengdu Science and Technology Project 2026-YF09-00015-SNNational Natural Science Foundation of China 82304789National Natural Science Foundation of China 82304969National Natural Science Foundation of China 82473871National Natural Science Foundation of China U2230123Sichuan Provincial Medical Youth Innovation Research Project Q22007Sichuan Science and Technology Program 2025ZDZX0134Sichuan Science and Technology Program 24NSFTD0024
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and immunosuppressive tumor microenvironment (iTME). We developed a ferritin-based nanoplatform (Fe-SH@Fn) co-delivering shikonin (SH) and Fe

Indexed as

FerroptosisImmunogenic Cell DeathLeukemia, Myeloid, AcuteNaphthoquinonesPolyphenolsAnimalsCell Line, TumorHumansMiceTumor MicroenvironmentNaphthoquinonesPolyphenolsshikoninacute myeloid leukemiaimmunosuppressionmetal‐polyphenol nanoplatformshikonintargeted drug delivery

Identifiers

PMID41773746
PMCPMC13170192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.